Physician profile
William C Pierce
NPI 1184718314
$8,557.30
in general payments reported to CMS, 2019-2025
65 companies · $2,218 in 2025
The $2,218 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $165 · 2021: $1,048 · 2022: $1,524 · 2023: $1,236 · 2024: $1,452 · 2025: $2,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,967 · Education: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,967.01 |
| Education | $938.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,116.20 | 2019-2025 | |
| Astellas Pharma US INC | $852.19 | 2019-2025 | Padcev, Xospata, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $718.66 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Pfizer INC. | $637.75 | 2019-2025 | |
| Janssen Biotech, INC. | $474.86 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Aveo Pharmaceuticals, INC. | $434.03 | 2022-2025 | Fotivda |
| Merck Sharp & Dohme LLC | $399.66 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $374.45 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Genzyme Corporation | $253.89 | 2019-2025 | |
| Incyte Corporation | $226.22 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Genentech USA, INC. | $191.01 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Ipsen Biopharmaceuticals, INC | $164.05 | 2019-2024 | Tazverik, Onivyde |
| Glaxosmithkline, LLC. | $157.87 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Amgen INC. | $146.18 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.23 | 2019-2025 | Libtayo |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.